In a recent study (Nature 516, 172-173, 11 December 2014), Wu and Izpisua evaluated systems for obtain iPS reprogrammed adult cells (somatic) in five recent studies.
In the first of these (Nature 516; 192-197, 2014), they discussed a novel reprogramming process that had given rise to a new type of reprogrammed pluripotent cells, which have been named F cells.
These cells, identified by Tonge et al. in the aforementioned study, are produced when the reprogramming factors are not silenced by other factors that are expressed in the host cells once pluripotency has been achieved.
A very important characteristic of F cells is that they can be produced on a large scale, which is an advantage for their possible clinical application in regenerative and reparatory medicine. However, their use may also have difficulties, as they could be carriers of mutations that have not hitherto been well controlled. In any case, attempts are being made to resolve this issue.
Undoubtedly these studies, in addition to their unquestionable scientific impact, are of great ethical interest, since it should not be forgotten that reprogrammed cells, especially iPS cells, offer great therapeutic possibilities without any ethical problems.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.